

PRODUCT INFORMATION



Ritonavir

Item No. 13872

CAS Registry No.: 155213-67-5
Formal Name: (3S,4S,6S,9S)-4-hydroxy-12-methyl-9-(1-methylethyl)-13-[2-(1-methylethyl)-4-thiazolyl]-8,11-dioxo-3,6-bis(phenylmethyl)-2,7,10,12-tetraazatridecanoic acid, 5-thiazolylmethyl ester

Synonyms: A-84538, ABT-538, NSC 693184, RTV

MF: C₃₇H₄₈N₆O₅S₂

FW: 720.9


Purity: ≥98%

UV/Vis.: λ_{max}: 238 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Ritonavir is supplied as a crystalline solid. A stock solution may be made by dissolving the ritonavir in the solvent of choice, which should be purged with an inert gas. Ritonavir is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of ritonavir in ethanol is approximately 5 mg/ml and approximately 15 mg/ml in DMSO and DMF.

Ritonavir is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ritonavir should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Ritonavir has a solubility of approximately 0.1 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Ritonavir is an HIV protease inhibitor.¹ It inhibits recombinant HIV-1 protease by 79% when used at a concentration of 0.5 nM. It inhibits HIV-1_{3B}-induced cell death in MT-4 human T cell leukemia cells (EC₅₀ = 25 nM) as well as cell death induced by HIV-1_{LAI}, HIV-2_{ROD}, and HIV-2_{EHO} in human MT-2 cells (IC_{50s} = 0.045, 0.13, and 0.24 μM, respectively).^{1,2} Ritonavir also inhibits the cytochrome P450 (CYP) isoform CYP3A (IC₅₀ = 0.14 μM).³ It inhibits CYP-mediated oxidative metabolism of the HIV protease inhibitors saquinavir (Item No. 9001893), indinavir (Item No. 15150), nelfinavir (Item No. 15369) in rat and human liver microsomes in a concentration-dependent manner.⁴ Ritonavir (10 mg/kg) also prevents decreases in plasma levels of these four compounds in rats. Formulations containing ritonavir have been used in the treatment of HIV-1 infection.

References

1. Kempf, D.J., Shan, H.L., Marsh, K.C., *et al.* *J. Med. Chem.* **41**(4), 602-617 (1998).
2. Koh, Y., Nakata, H., Maeda, K., *et al.* *Antimicrob. Agents Chemother.* **47**(10), 3123-3129 (2003).
3. Kumar, G.N., Dykstra, J., Roberts, E.M., *et al.* *Drug Metab. Dispos.* **27**(8), 902-908 (1999).
4. Kempf, D.J., Marsh, K.C., Kumar, G., *et al.* *Antimicrob. Agents Chemother.* **41**(3), 654-660 (1997).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/19/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM